Company Overview and News

1
Pulse Biosciences Inc.'s (PLSE) CEO Darrin Uecker on Q2 2018 Results - Earnings Call Transcript

2018-08-01 seekingalpha - 1
Good day, ladies and gentlemen and welcome to the Pulse Biosciences Investor Update Call. At this time all participants are in listen-only. Later we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions]. As a reminder today's program is being recorded.
PLSE

1
PLSE / Pulse Biosciences, Inc. 8-K (Current Report)

2018-07-31 sec.gov - 1
8-K (7-31-2018) 
PLSE

 
PLSE / Pulse Biosciences, Inc. 10-Q (Quarterly Report)

2018-07-31 sec.gov
20180630- Q2   <
PLSE

 
PLSE / Pulse Biosciences, Inc. 8-K (Current Report)

2018-07-31 sec.gov
8-K (7-31-2018) 
PLSE

180
The Alfred E. Mann Foundation for Scientific Research is Pleased to Announce the Appointment of Robert Greenberg, MD, PhD to the Role of Executive Chairman

2018-06-27 accesswire
VALENCIA, CA / ACCESSWIRE / June 27, 2018 / The Alfred E. Mann Foundation for Scientific Research, ''AMF'', an independent non-profit medical device incubator committed to developing and commercializing innovative solutions for significant unmet or poorly met medical conditions, today announced the appointment of Robert Greenberg, MD, PhD to the role of Executive Chairman. ''I have enjoyed interacting with Dr.
BSX EYES PLSE

81
PLSE / Pulse Biosciences, Inc. null

2018-06-24 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0X(# @;V)J#3P\+TQI;F5A
PLSE

81
PLSE / Pulse Biosciences, Inc. null

2018-06-24 sec.gov
SEC Acceleration Request (5-17-2018) May 17, 2018 
PLSE

88
PLSE / Pulse Biosciences, Inc. null

2018-06-18 sec.gov - 7
Form 8-K12B 
PLSE

81
PLSE / Pulse Biosciences, Inc. 8-K (Current Report)

2018-05-28 sec.gov
8K 2018-05-23  UNITED S
PLSE

89
PLSE / Pulse Biosciences, Inc. 424B3 (Prospectus)

2018-05-22 sec.gov - 8
S-3 424 b (3)  Filed Pursuant to Rule 424(b)(3)
PLSE

81
Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon. My name is Julie and I will be your conference operator today. At this time, I would like to welcome everyone to the Pulse Biosciences Investor Update Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session [Operator Instructions].
COMD PLSE

102
PLSE / Pulse Biosciences, Inc. S-3

2018-05-09 sec.gov - 21
S-3 As filed with the Securities and Exchange Commission on May 9, 2018 Registration No. 333- &nb
PLSE

86
PLSE / Pulse Biosciences, Inc. 8-K (Current Report)

2018-05-08 sec.gov - 5
8-K (5-8-2018) 
PLSE

83
PLSE / Pulse Biosciences, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov - 2
20180331- Q1  
PLSE

PLSE: Pulse Biosciences Analysis and Research Report

2018-02-19 - Asif

Pulse Biosciences is a clinical-stage medical technology company developing a non-thermal tissue treatment platform technology based upon its proprietary Nano-Pulse Stimulation (“NPS”) technology and pursuing applications in oncology, dermatology, general tissue treatment and veterinary medicine. NPS is a novel patented technology which leverages nano-second duration energy pulses that have demonstrated effective local tumor control and the initiation of an adaptive immune response in pre-clinical studies. Pulse Biosciences is pursuing a number of clinical applications for NPS, including oncology, dermatology, aesthetics and other minimally invasive applications where the company believe NPS has the potential to compare favorably with current therapies and treatments. Pulse Biosciences is currently conducting research and development activities in pursuit of commercial applications for its NPS technology, but Pulse Biosciences has not yet commercialized or recognized revenue from its t...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PLSE / Pulse Biosciences, Inc. on message board site Silicon Investor.

premier laser sys inc (plsia new plsea.o) premier laser sys inc (plsia new plsea.o) premier laser sys inc (plsia new plsea.o)
CUSIP: 74587B101